

IN THE CLAIMS

Claims 1-15 (Cancelled)

Claim 16 (Currently Amended): An aerosol

which is produced from a solution comprising consisting of:

[[a]] one or more solubilized active material(s),

a propellant comprising consisting of a mixture of HFA 227 and HFA 134a, and

optionally,

a low volatility component, or a cosolvent, or both,

ethanol as a cosolvent;

wherein the ratio of HFA 227:HFA 227:HFA 134a ranges from 10:90 to 90:10 and

said ratio is selected to produce an aerosol having an MMAD (mass median aerodynamic diameter) greater than 2 μ m, wherein at least 40% of said aerosol is composed of fine particles having a diameter of less than 4.7 μ m;

wherein said aerosol has an MMAD greater than 2 μ m, and

wherein at least 40% of said aerosol is composed of fine particles having a diameter of less than 4.7 μ m

, and

wherein the MMAD of said aerosol is greater than 2 μ m and the fine particle dose (<4.7 μ m) is >40%.

Claim 17 (Currently Amended): The aerosol of Claim 16, wherein the percentage the fine particle dose (<4.7 μ m) of particles having a diameter of less than 4.7 μ m in said aerosol is >50%.

Claims 18-27 (Cancelled)

Claim 28 (Previously Presented): The aerosol of Claim 16, wherein the active material comprises a $\beta 2$ agonist.

Claim 29 (Previously Presented): The aerosol of Claim 16, wherein the active material comprises a corticosteroid.

Claim 30 (Previously Presented): The aerosol of Claim 16, wherein the active material comprises an anti-cholinergic drug.

Claim 31 (Previously Presented): An aerosol inhaler that produces the aerosol of Claim 16.

Claim 32 (Previously Presented): An aerosol inhaler that produces the aerosol of Claim 17.

Claim 33 (Currently Amended): An aerosol inhaler that produces the aerosol of Claim 16, wherein part or all of the internal surface(s) comprise at least a portion of the internal surface(s) of said aerosol inhaler comprise stainless steel, anodized aluminum or an inert organic coating.